Denali Therapeutics Inc.

DNLISEC EDGAR

Biological Products, (No Diagnostic Substances)(DE)CIK: 1714899

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	$330.5M	$105.1M	$48.7M	$335.6M	$26.3M
Research and Development Expense	$423.9M	$358.7M	$265.4M	$212.6M	$193.4M
Operating Expenses	$527.2M	$449.2M	$344.4M	$272.9M	$239.9M
Operating Income (Loss)	-$196.7M	-$340.7M	-$295.8M	$62.7M	-$213.2M
Nonoperating Income (Expense)	—	—	$4.6M	$9.2M	$15.2M
Income Tax Expense (Benefit)	$30.0K	$21.0K	-$575.0K	$823.0K	-$351.0K
Net Income (Loss) Attributable to Parent	-$145.2M	-$326.0M	-$290.6M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$1.4B	$1.2B	$1.5B	$1.4B	$1.6B
Assets, Current	$864.4M	$1.1B	$1.4B	$897.2M	$1.5B
Cash and Cash Equivalents, at Carrying Value	$175.0M	$127.1M	$218.0M	$293.5M	$507.1M
Liabilities	$144.5M	$123.0M	$417.8M	$441.9M	$453.7M
Liabilities, Current	$102.2M	$78.0M	$363.9M	$378.2M	$71.7M
Accounts Payable, Current	$11.1M	$9.5M	$2.8M	$4.8M	$1.1M
Stockholders' Equity Attributable to Parent	$1.0B	$962.3M	$1.2B	$394.9M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$358.0M	-$244.7M	-$211.4M	$416.2M	-$151.6M
Net Cash Provided by (Used in) Investing Activities	$249.3M	-$141.4M	-$21.6M	-$623.2M	$147.7M
Net Cash Provided by (Used in) Financing Activities	$17.8M	$310.7M	$19.3M	$634.7M	$6.2M
Payments to Acquire Property, Plant, and Equipment	$12.9M	$17.8M	$8.5M	$3.1M	$17.9M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)